Presentation is loading. Please wait.

Presentation is loading. Please wait.

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Published byΝηλεύς Μέλιοι Modified over 5 years ago

Similar presentations

Presentation on theme: "Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension."— Presentation transcript:

1 Diagnostic applications of metabolic dysregulation in pulmonary hypertension.
Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Differences in the profiles of extracellular metabolites in circulating blood may reflect metabolic reprogramming in pulmonary arterial hypertension versus healthy individuals. IDO-TM: indoleamine 2,3-dioxygenase-dependent tryptophan metabolites; PAH: pulmonary arterial hypertension. Stephen Y. Chan, and Lewis J. Rubin Eur Respir Rev 2017;26:170094 ©2017 by European Respiratory Society

Download ppt "Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension."

Similar presentations

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Diagnostic algorithm for pulmonary arterial hypertension (PAH).

Diagnostic algorithm for pulmonary arterial hypertension (PAH).
a) Normal parasternal long-axis view.

a) Normal parasternal long-axis view.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Timeline of approval of therapies for pulmonary arterial hypertension.

Timeline of approval of therapies for pulmonary arterial hypertension.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
A) Pulmonary angiography, showing a stenosis in the subsegment of the 10th segmental artery (anterior view); b) the catheter is introduced into a web stenosis;

A) Pulmonary angiography, showing a stenosis in the subsegment of the 10th segmental artery (anterior view); b) the catheter is introduced into a web stenosis;
Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.
Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.
Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)
The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]

The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]
Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.
Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.
Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.
Scoring system for health-related quality of life (HRQoL) scales [33, 40]. Scoring system for health-related quality of life (HRQoL) scales [33, 40]. SF-36:

Scoring system for health-related quality of life (HRQoL) scales [33, 40]. Scoring system for health-related quality of life (HRQoL) scales [33, 40]. SF-36:
Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Similar presentations

Ads by Google